Teva charged in US price-fixing investigation | Financial Times
Teva Pharma Appoints Novartis, Biogen Vet as New President and CEO | BioSpace
Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma
Teva Pharmaceutical will cut 7,000 jobs and close plants to reduce costs
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Teva Pharmaceutical Industries and opioid settlement: What to know
Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States | Business Wire
Teva enters opioid settlement agreement with US state Rhode Island
Outsourcing active medicine ingredients leaves EU patients at risk
Teva Pharmaceutical Industries. Information about the issuer. (LEI 549300BAFGM4RC74ZJ94, SWIFT TEVPILITXXX). News and credit ratings. Tables with accounting and financial reports.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is expected to earn $0.53 per share in the first quarter of 2023. – Best stocks to buy now, Stocks to buy